Cargando…
A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom
BACKGROUND: Envenomation caused by multiple stings from Africanized honeybees Apis mellifera constitutes a public health problem in the Americas. In 2015, the Brazilian Ministry of Health reported 13,597 accidents (incidence of seven cases per 100,000 inhabitants) with 39 deaths (lethality of 0.25%)...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356296/ https://www.ncbi.nlm.nih.gov/pubmed/28331487 http://dx.doi.org/10.1186/s40409-017-0106-y |
_version_ | 1782515799776296960 |
---|---|
author | Barbosa, Alexandre Naime Boyer, Leslie Chippaux, Jean-Philippe Medolago, Natalia Bronzatto Caramori, Carlos Antonio Paixão, Ariane Gomes Poli, João Paulo Vasconcelos Mendes, Mônica Bannwart dos Santos, Lucilene Delazari Ferreira, Rui Seabra Barraviera, Benedito |
author_facet | Barbosa, Alexandre Naime Boyer, Leslie Chippaux, Jean-Philippe Medolago, Natalia Bronzatto Caramori, Carlos Antonio Paixão, Ariane Gomes Poli, João Paulo Vasconcelos Mendes, Mônica Bannwart dos Santos, Lucilene Delazari Ferreira, Rui Seabra Barraviera, Benedito |
author_sort | Barbosa, Alexandre Naime |
collection | PubMed |
description | BACKGROUND: Envenomation caused by multiple stings from Africanized honeybees Apis mellifera constitutes a public health problem in the Americas. In 2015, the Brazilian Ministry of Health reported 13,597 accidents (incidence of seven cases per 100,000 inhabitants) with 39 deaths (lethality of 0.25%). The toxins present in the venom, which include melittin and phospholipase A(2), cause lesions in diverse organs and systems that may be fatal. As there has been no specific treatment to date, management has been symptomatic and supportive only. METHODS: In order to evaluate the safety and neutralizing capacity of a new apilic antivenom, as well as to confirm its lowest effective dose, a clinical protocol was developed to be applied in a multicenter, non-randomized and open phase I/II clinical trial. Twenty participants with more than five stings, aged more than 18 years, of both sexes, who have not previously received the heterologous serum against bee stings, will be included for 24 months. The proposed dose was based on the antivenom neutralizing capacity and the number of stings. Treatment will be administered only in a hospital environment and the participants will be evaluated for a period up to 30 days after discharge for clinical and laboratory follow-up. RESULTS: This protocol, approved by the Brazilian regulatory agencies for ethics (National Commission for Ethics on Research – CONEP) and sanitation (National Health Surveillance Agency – ANVISA), is a guideline constituted by specific, adjuvant, symptomatic and complementary treatments, in addition to basic orientations for conducting a clinical trial involving heterologous sera. CONCLUSIONS: This is the first clinical trial protocol designed specifically to evaluate the preliminary efficacy and safety of a new antivenom against stings from the Africanized honeybee Apis mellifera. The results will support future studies to confirm a new treatment for massive bee attack that has a large impact on public health in the Americas. |
format | Online Article Text |
id | pubmed-5356296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53562962017-03-22 A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom Barbosa, Alexandre Naime Boyer, Leslie Chippaux, Jean-Philippe Medolago, Natalia Bronzatto Caramori, Carlos Antonio Paixão, Ariane Gomes Poli, João Paulo Vasconcelos Mendes, Mônica Bannwart dos Santos, Lucilene Delazari Ferreira, Rui Seabra Barraviera, Benedito J Venom Anim Toxins Incl Trop Dis Research BACKGROUND: Envenomation caused by multiple stings from Africanized honeybees Apis mellifera constitutes a public health problem in the Americas. In 2015, the Brazilian Ministry of Health reported 13,597 accidents (incidence of seven cases per 100,000 inhabitants) with 39 deaths (lethality of 0.25%). The toxins present in the venom, which include melittin and phospholipase A(2), cause lesions in diverse organs and systems that may be fatal. As there has been no specific treatment to date, management has been symptomatic and supportive only. METHODS: In order to evaluate the safety and neutralizing capacity of a new apilic antivenom, as well as to confirm its lowest effective dose, a clinical protocol was developed to be applied in a multicenter, non-randomized and open phase I/II clinical trial. Twenty participants with more than five stings, aged more than 18 years, of both sexes, who have not previously received the heterologous serum against bee stings, will be included for 24 months. The proposed dose was based on the antivenom neutralizing capacity and the number of stings. Treatment will be administered only in a hospital environment and the participants will be evaluated for a period up to 30 days after discharge for clinical and laboratory follow-up. RESULTS: This protocol, approved by the Brazilian regulatory agencies for ethics (National Commission for Ethics on Research – CONEP) and sanitation (National Health Surveillance Agency – ANVISA), is a guideline constituted by specific, adjuvant, symptomatic and complementary treatments, in addition to basic orientations for conducting a clinical trial involving heterologous sera. CONCLUSIONS: This is the first clinical trial protocol designed specifically to evaluate the preliminary efficacy and safety of a new antivenom against stings from the Africanized honeybee Apis mellifera. The results will support future studies to confirm a new treatment for massive bee attack that has a large impact on public health in the Americas. BioMed Central 2017-03-16 /pmc/articles/PMC5356296/ /pubmed/28331487 http://dx.doi.org/10.1186/s40409-017-0106-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Barbosa, Alexandre Naime Boyer, Leslie Chippaux, Jean-Philippe Medolago, Natalia Bronzatto Caramori, Carlos Antonio Paixão, Ariane Gomes Poli, João Paulo Vasconcelos Mendes, Mônica Bannwart dos Santos, Lucilene Delazari Ferreira, Rui Seabra Barraviera, Benedito A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom |
title | A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom |
title_full | A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom |
title_fullStr | A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom |
title_full_unstemmed | A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom |
title_short | A clinical trial protocol to treat massive Africanized honeybee (Apis mellifera) attack with a new apilic antivenom |
title_sort | clinical trial protocol to treat massive africanized honeybee (apis mellifera) attack with a new apilic antivenom |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356296/ https://www.ncbi.nlm.nih.gov/pubmed/28331487 http://dx.doi.org/10.1186/s40409-017-0106-y |
work_keys_str_mv | AT barbosaalexandrenaime aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT boyerleslie aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT chippauxjeanphilippe aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT medolagonataliabronzatto aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT caramoricarlosantonio aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT paixaoarianegomes aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT polijoaopaulovasconcelos aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT mendesmonicabannwart aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT dossantoslucilenedelazari aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT ferreiraruiseabra aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT barravierabenedito aclinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT barbosaalexandrenaime clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT boyerleslie clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT chippauxjeanphilippe clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT medolagonataliabronzatto clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT caramoricarlosantonio clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT paixaoarianegomes clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT polijoaopaulovasconcelos clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT mendesmonicabannwart clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT dossantoslucilenedelazari clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT ferreiraruiseabra clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom AT barravierabenedito clinicaltrialprotocoltotreatmassiveafricanizedhoneybeeapismelliferaattackwithanewapilicantivenom |